MMP2 AS A PREDICTIVE BIOMARKER OF RESPONSE TO ANTIANGIOGENIC THERAPY AND SURVIVAL AFTER THERAPY IN CANCER PATIENTS

摘要

The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.